Andrew Zelenetz

Trials

Studies that name Andrew Zelenetz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:02 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04416451 · A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

  Memorial Sloan Kettering Cancer Center · active not recruiting · Marginal Zone Lymphoma · principal investigator
• Ph2
  NCT03824483 · Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  Memorial Sloan Kettering Cancer Center · active not recruiting · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) · principal investigator
• Ph1/Ph2
  NCT02282358 · Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

  Memorial Sloan Kettering Cancer Center · terminated · Lymphoma, Relapsed and Refractory, Diffuse Large B-Cell Lymphoma and Follicular Lymphoma · principal investigator
• Ph1/Ph2
  NCT01484093 · Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

  Memorial Sloan Kettering Cancer Center · completed · Mantle Cell Lymphoma · principal investigator
• Ph2
  NCT00712582 · Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

  Memorial Sloan Kettering Cancer Center · completed · Non-Hodgkin's Lymphoma · principal investigator
• Ph2
  NCT00005964 · Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

  Alliance for Clinical Trials in Oncology · completed · Lymphoma · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 00:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• MSK SPORE in Lymphoma
  P50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2016 to 2020 · $2,138,999 awarded in 2020
  Same name and institution; not confirmed by an ID
• MODULATION OF BCL-2 EXPRESSION BY CLASS SWITCH DELETION
  R01CA058842 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1993 to 1996 · $118,122 awarded in 1996
  Same name and institution; not confirmed by an ID
• MOLECULAR DIAGNOSIS AND PATHOGENSIS OF LYMPHOMA
  R01CA061429 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 1993 to 1996 · $227,638 awarded in 1996
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Cancer and Leukemia Group B
  U10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013
  Named on NCT00005964